Article
Genentech Rejects Roche Proposal
Author(s):
The American biotech giant Genentech, Inc. has rejected an offer by the Swiss drug-maker Roche to acquire the 44% of Genentech it does not already own, but said it would be willing to consider a higher bid.
The American biotech giant Genentech, Inc. (South San Francisco, CA) has rejected an offer by the Swiss drug-maker Roche (Basel, Switzerland) to acquire the 44% of Genentech it does not already own, but said it would be willing to consider a higher bid.
Genentech said Roche’s offer of $89 a share “substantially undervalues the company” and that it would consider an offer that “reflects the significant benefits that would accrue to Roche as a result of full ownership.”
Last month, Roche had made an offer to acquire all of the outstanding shares of Genentech stock not owned by Roche at a price of $89 in cash per share. Genentech had formed a special committee to review the proposal.
For more information on the Roche offer, see BioPharm’s previous news coverage.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
